A high incidence of nonrelapse mortality (NRM) has limited the use of allogeneic transplantation for poor prognosis non-Hodgkin's lymphoma (NHL). We sought to improve the outcome of allografting by utilizing Filgrastim-mobilized peripheral blood stem cells (PBSC) in combination with either standard ablative or reducedintensity conditioning. A total of 21 patients with intermediate/high-grade lymphoma and seven patients with low-grade histology were enrolled on protocols using PBSC. All patients were considered high risk for recurrence and/or NRM because of age 450 (n ¼ 16), refractory disease (n ¼ 17), failed autologous transplant (n ¼ 11) and abnormal organ function (n ¼ 2). In all, 17 patients received ablative regimens and 11 received modified conditioning including fludarabine, intravenous busulfan and ATG. Tacrolimus and mini-dose methotrexate were used for graft-versus-host-disease (GVHD) prophylaxis. Median follow-up was 38 months. Diseasefree and overall survival were 57 and 58%. Seven of the 11 patients who relapsed after a previous transplant remain disease free. Four of the 10 patients with recurrent/ persistent disease post transplant responded to additional therapy including withdrawal of immunosuppression7 DLI. These results support a potent graft-versus-lymphoma effect and suggest that patients who relapse after an autologous transplant can be salvaged with an allogeneic transplant.
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High-dose chemotherapy and autologous stem cell rescue is a potentially curative therapy for chemosensitive nonHodgkin's lymphoma (NHL). For patients with resistant disease and those who relapse after autologous stem cell transplant, the outcome is poor with currently available treatment. Unfortunately, there has been little improvement in the efficacy of high-dose autologous transplant regimens in the last decade, suggesting that alternative approaches will be necessary to further improve cure rates in patients with poor prognosis disease.
Patients with recurrent or resistant NHL may be cured with allogeneic bone marrow transplantation, but low relapse rates have been consistently offset by high rates of nonrelapse mortality. [1] [2] [3] [4] [5] [6] The latter problem has resulted in the exclusion of most older patients and those with comorbid disease. Similarly, even in younger, healthier patients who have relapsed after an autologous transplant, allogeneic transplantation with standard conditioning has been associated with a prohibitive risk of treatment-related mortality (TRM). [7] [8] [9] Improvements in transplant regimens and supportive measures are therefore particularly relevant for NHL patients who have frequently been heavily treated prior to consideration of an allogeneic transplant. The development of less intensive, but highly immunosuppressive conditioning regimens that rely on possible graft-versus-tumor effects have expanded the number of patients who are candidates for allografts, including those who relapse after a prior autologous transplant. [10] [11] [12] [13] In addition, the use of mobilized peripheral blood stem cells (PBSC) has recently been shown to increase the therapeutic index of allogeneic transplantation in high-risk patients treated with ablative regimens. 14, 15 As a result, beginning in 1997, we offered allogeneic PBSC transplantation to patients that we considered incurable with further standard therapy (including autologous transplant) and to patients who had relapsed after an autologous transplant. Patients underwent transplantation after either a traditional myeloablative conditioning regimen or a less intensive 'modified regimen', based on patient age, medical condition and disease status.
Patients and methods

Eligibility
Between August 1997 and December 2000, 28 consecutive patients with NHL were enrolled on clinical protocols utilizing PBSC as part of an overall strategy to reduce treatment-related toxicity for high-risk patients undergoing allogeneic transplantation. Protocols were approved by the Yale Human Investigations Committee and informed consent was obtained from all participants. Protocol #9751 included patients with hematologic malignancy with normal organ function for whom a traditional myeloablative regimen was combined with an allogeneic PBSC graft (Ablative protocol). The choice of conditioning regimen for these patients was based on prior treatment history. Patients were required to have normal organ function, ECOG performance status o2, and age less than 60 years. Protocol 10447 employed a reduced-intensity conditioning regimen and was intended for patients with comorbidity or advanced age who would be considered poor candidates for allogeneic transplantation (modified protocol). Patients enrolled on this protocol could be up to 65 years of age and were required to have ECOG performance status p2. Organ function requirements were not specified for modified conditioning. Based on earlier reports, 8, 16 patients with indolent low-grade lymphoma were also considered eligible for this protocol regardless of age or organ function. All patients had biopsy-proven NHL reviewed at our institution.
Patients were required to have a 5/6 or 6/6 HLA compatible family donor in the graft-versus-host disease (GVHD) direction, as determined by serologic methods for HLA Class I antigens and at least low-resolution molecular typing for HLA class II antigens.
Conditioning regimens
The majority of patients receiving myeloablative regimens were treated with either high-dose BEAM 17 or a combination of total body irradiation (1200 cGy in eight fractions over 4 days) and cyclophosphamide (60 mg/kg/day Â 2 days). The modified conditioning regimen included fludarabine, busulfan and antithymocyte globulin as described by Slavin et al with the exception that busulfan (Busulfext) was administered intravenously at a dose of 0.8 mg/kg every 6 h for eight doses on days -6 and -5 of the conditioning regimen. Horse ATG (Atgamt), 10 mg/kg was given daily for 4 days on days -4 through -1.
Donor stem cell mobilization
Donors were mobilized with filgrastim (Neupogent, Amgen) at a dose of 10 mg/kg s.c. daily (ablative protocol) or 6 mcg/kg every 12 h (modified protocol) and leukapheresis was initiated on the 4th day of filgrastim administration. A goal of 5 Â 10 6 CD34 þ cells/kg recipient body weight, and a minimum of 2 Â 10 6 CD34 þ cells/kg recipient body weight was set.
Supportive care
All patients received conditioning and early post transplant care in isolation rooms with positive pressure air flow and HEPA filters. Prophylactic antibiotics including ciprofloxacin, acyclovir, and fluconazole were continued until neutrophil recovery. Filgrastim, 5 mg/kg s.c. was administered from day þ 7 after transplant until sustained neutrophil recovery. A total of 14 patients also received metronidazole 500 mg every 8 h until neutrophil recovery.
Prophylaxis for venoocclusive disease of the liver included enoxaparin, 40 mg s.c. daily and actigall 300 mg every 12 h from the first day of conditioning until day þ 21 or hospital discharge. Enoxaparin was held for invasive procedures or if gross evidence of bleeding was present. CMV antigen was monitored at weekly intervals from WBC engraftment until day 100. PCP prophylaxis consisted of oral trimethoprim/ sulfamethoxisole three times weekly or inhaled pentamidine monthly beginning day þ 30 post transplant.
GVHD prophylaxis/treatment
GVHD prophylaxis consisted of tacrolimus starting on day -1 as a continuous i.v. infusion, initially at a starting dose of 0.03 mg/kg/24 h. Following our initial experience in this older population that initial blood levels of tacrolimus frequently exceeded the desired range, the initial starting dose was lowered to 0.015 mg/kg/24 h. Doses were adjusted to maintain levels between 5 and 15 ng/ml. Methotrexate 5 mg/m 2 was administered by i.v. push on days þ 1, þ 3 and þ 6 provided patients had normal renal and hepatic function and absence of significant third space fluid. Tacrolimus was tapered at 6 months in the absence of GVHD. Tacrolimus was discontinued prematurely in patients suffering disease relapse or progression prior to 6 months, in the absence of GVHD. Patients developing 4grade I acute GVHD were treated with methylprednisolone at an initial dose of 2 mg/kg/day. Patients failing to respond to steroids or unable to wean from steroids were treated with alternate immunosuppressive agents such as daclizumab, infliximab, mycophenolate or sirolimus. Antithymocyte globulin was not used for salvage therapy of refractory GVHD.
Definitions of toxicity and response
Early regimen-related toxicity was evaluated using established transplant-specific criteria. 18 Acute and chronic GVHD was graded using consensus criteria. 19 Patients were considered to have achieved a complete remission (CR) if all evidence of disease resolved. Patients with previously documented gallium-avid disease were also required to have a negative gallium scan. Disease evaluations including CT scans, gallium scan (if appropriate) and bone marrow biopsy were performed on days þ 30, þ 100, þ 180, þ 360, then at least yearly. Engraftment status was analyzed by FISH on regularly obtained bone marrow specimens for sex chromosomes in sex-mismatched donor/ recipient pairs and VNTR analysis for sex-matched pairs.
Statistical methods
Statistical analysis was performed using a commercial statistics program (SPSS 11.0 for the Mac OS X, SPSS, Inc., Chicago, IL, USA). Actuarial probabilities of diseasefree and overall survival, acute GVHD and nonrelapse mortality (NRM) were calculated according to the method of Kaplan and Meier. 20 Differences between outcomes were compared using the log rank test.
Allogeneic PBSC transplantation for high-risk NHL
Results
Patient characteristics
Patient characteristics and risk factors are summarized in Tables 1 and 2 . All patients were considered high-risk for TRM based on the presence of either age 450, chemorefractory disease or prior transplant. In all, 24 of 28 patients had either chemotherapy refractory disease or had recurrence following a prior transplant; 10 patients had failed a prior autologous transplant following a chemotherapy-only conditioning regimen (BEAM) supported by PBSC. The remaining patient had recurrence following a Tcell-subset-depleted allogeneic bone marrow transplant (and subsequent T-cell-subset-depleted DLI), but had no prior history of GVHD. Patients who failed a prior transplant had recurrence at median of 16 months and underwent allogeneic transplant as a second transplant procedure at a median of 26 months (range 4-54 months) following their initial transplant. Seven of these patients had chemotherapy-sensitive disease.
Graft characteristics and engraftment
Adequate numbers of progenitors were collected from all donors following Filgrastim administration after 1-4 (median ¼ 2) leukapharesis procedures (Table 3) . Neutrophils and platelets engrafted promptly following PBSC transplant. One patient failed to achieve sustained neutrophil engraftment following ablative conditioning and died on day þ 26 in the setting of multiorgan system failure. An additional patient failed to achieve sustained platelet counts greater than 20 000 and was found to have evidence of immune-mediated peripheral destruction of platelets, including adequate bone marrow megakaryocyte numbers, positive antiplatelet antibody tests and a high reticulated platelet index. 21 FISH analysis for sex chromosomes revealed only donor cells. All other patients engrafted promptly. Informative data regarding BM chimeric status were available for all patients remaining alive at day þ 30 post transplant. For patients treated with 
Toxicity
Regimen-related toxicities are summarized in Table 4 . Lifethreatening toxicities were uncommon in patients receiving either type of conditioning. Grade II toxicities were common but less frequent with modified conditioning. For instance, grade II mucositis occurred in four of 11 patients treated with the modified conditioning regimen. Three patients died prior to day þ 100 of sepsis/multiorgan failure, disseminated aspergillus infection and disease progression, with concurrent Grade IV GVHD. Febrile neutropenia occurred in most patients although no Gramnegative infections occurred during the neutropenic period. Six episodes of Gram-positive bacteremia occurred, one of which resulted in sepsis/multiorgan failure as above.
Patients who received modified conditioning were discharged a median of 5 days earlier than those receiving ablative conditioning regimens. There were no cases of PCP or CMV pneumonia. One nonrelapse death occurred beyond day 100 from sequelae of chronic GVHD. The actuarial risks of day þ 100 and overall NRM were 7 and 19%, respectively.
GVHD
The probability of developing grades II-IV acute GVHD was 26%. Severe GVHD (grades III-IV) occurred in two patients. In all, 24 patients were evaluable for chronic GVHD. Extensive chronic GVHD occurred in 21/24 patients and was de novo in nine patients and quiescent in 10. Five patients had adverse risk features including steroid refractory disease, progressive onset or extensive skin involvement. In the remaining patients such features were not present. One death has been attributed to chronic GVHD. In seven patients, the development of chronic GVHD was directly related to maneuvers used to treat disease relapse such as withdrawal of immunosuppression and administration of donor lymphocytes. In total, 10 of 18 patients remained on immunosuppression. The current median Karnofsky performance status of surviving patients is 90% (range 80-100).
Relapse and survival
A total of 21 patients achieved a CR or continued CR at the first evaluation post transplant (Table 3) . Four patients achieved a partial remission (PR) and three patients had no response/progression. Ten patients have had progressive or recurrent lymphoma post transplant and seven have died of disease. In all, 18 patients remain alive with a median follow-up of 38 months (range ¼ 24-62 months). All surviving patients are currently free of disease including the two patients who relapsed following allotransplant and achieved remission after additional post transplant therapy including withdrawal of immunosuppression and DLI. All of the patients with mantle cell lymphoma remain disease free. Of the 17 patients with other aggressive lymphomas, 10 are currently disease free, including two patients who received DLI and other treatment for post transplant relapse. Only two patients with these histologies received modified conditioning which failed to control disease in both instances. Kaplan-Meier estimates of disease free and overall survival at 5 years are 57 and 58%, respectively ( Figure 1 ). The only factor associated with disease free and overall survival on univariate analysis was pretransplant disease status, which was significantly associated with a poorer outcome. (Figure 2 ). Disease-free survival for patients undergoing a second transplant is 55% (Figure 3 ). For those patients who received a second transplant, median time to relapse after prior transplant was 16 months but this has not yet been reached following allogeneic transplant.
Treatment of disease following transplant
A total of 10 patients developed recurrent or progressive disease following transplant. Seven patients were treated with the intention of inducing a graft versus lymphoma effect by withdrawing immunosuppression and, in six cases, administering donor lymphocytes (DLI). The dose of Table 4 Grades III-IV regimen-related toxicity Allogeneic PBSC transplantation for high-risk NHL S Seropian et al CD3 þ lymphocytes administered ranged from 5 Â 10 7 to 1 Â 10 8 CD3 þ cells/kg. Additional therapies administered to some patients at the time of recurrence also included rituximab, interferon and radiotherapy to isolated sites of disease. Four patients responded to this strategy, all of whom developed GVHD. Two of these patients remain in CR at 27 and 40 months post transplant. One patient died of disease progression and one died in continued remission at 37 months post transplant of sequelae of chronic GVHD. Of the seven patients who failed to achieve a CR as a result of the conditioning regimen, five died of disease, one died of chronic GVHD in remission (as above) and one remains disease free after XRT, withdrawal of immunosuppression and DLI.
Discussion
The present study provides additional evidence for the potentially curative role of allogeneic transplantation in patients with high risk and poor prognosis intermediate and low-grade lymphoma. Moreover, by triaging patients to either a standard ablative or a reduced-intensity conditioning regimen supported by PBSC, NRM was relatively low in this older, high-risk population.
It was particularly encouraging that seven of 11 patients who had relapsed after a prior transplant are currently alive, free of disease. These results stand in marked contrast to several previous reports of allogeneic transplantation for recurrent NHL following failed prior transplant, in which the results have been so poor as to suggest that such therapy should not be offered. 7, 9 Our results suggest that for patients with a good performance status and especially for those who remain chemosensitive at the time of relapse, allogeneic transplant is an effective, reasonably safe treatment.
Our study does not address the most appropriate conditioning regimen for patients with different types of NHL although our results suggest that reduced-intensity conditioning regimens may be the preferred therapy for select patients. The favorable results that we observed in patients with low-grade lymphoma despite multiple prior treatments are in agreement with Khouri et al, 13 who reported an 84% 2-year disease-free survival with a reduced-intensity program, supporting the concept of a robust GVL effect for indolent lymphomas.
Our results also support a strong GVL effect in MCL. Four of four patients with resistant (one) and relapsed (three) MCL are disease free after allogeneic transplant. All three elderly patients who had relapsed after autologous transplant remain disease free after a second, reducedconditioning allogeneic transplant. Although apparent cures of MCL with allogeneic transplant after autologous transplant failure have been described in case reports, [22] [23] [24] these patients were conditioned with high-dose therapy regimens. Khouri et al 25 have also described a potent GVL effect in MCL. 25 In their series, none of the 15 patients who achieved donor chimerism experienced a relapse, including one patient with drug-resistant disease who received a lowintensity regimen. Unfortunately, after aggressive conditioning regimens NRM was high in patients with chemoresistant disease. As the median age of patients with MCL is over age 60 years, standard ablative programs are not likely to be appropriate for most allogeneic transplant candidates, particularly if they have already received intensive prior treatment. The low relapse rate in the Khouri et al series as well as the results in our own small series of patients suggests that the GVL effect in MCL is similar to that observed in follicular small cell lymphoma. As a result, reduced-conditioning regimens should be further explored in this population.
The role of allogeneic transplant in patients with relapsed or refractory intermediate-grade lymphoma (excluding MCL) has not been determined. In the current series, allogeneic transplant was reserved for patients that were predicted to have a low cure rate with autologous transplant or who had relapsed after autologous transplant. Eight of 13 such patients treated with standard ablative programs have achieved durable CRs including three of five patients who had relapsed after autologous transplants. Only two patients received reduced-intensity conditioning, used the International Prognostic Index at the time of relapse (S-IPI) to identify patients who were unlikely to be cured with high-dose therapy and autologous transplant. 26 Alternatively, physiologic studies of chemosensitivy such as that obtained by PET scan may allow patients with a poor prognosis to be identified earlier in treatment. 27 By virtue of a low rate of NRM, the major cause of treatment failure in the current study was disease progression. Importantly, four patients with relapsed or progressive disease after allogeneic transplant experienced subsequent responses, including three that were durable, after withdrawal of immunosuppression plus or minus DLI and additional treatment. We are not aware of other reports of patients with intermediate-grade lymphoma who have achieved durable remission following relapse after allogeneic transplant. Withdrawal of immunosuppression plus or minus DLI was used in conjunction with other therapies to control disease growth such as localized radiotherapy and rituximab. Rituximab is an attractive post transplant drug because of its favorable safety profile and because its antineoplastic activity should not interfere with a GVL effect. The introduction of other anti-B-cell monoclonal antibodies may provide additional treatment alternatives in patients with persistent or recurrent disease after transplant.
Consistent with multiple other reports in which PBSC were used, 14, 15, 28 the risk of severe acute GVHD in this series does not appear to be greater than that expected with bone marrow. In addition, although a high rate of severe acute GVHD has been described in patients with prior autologous transplants, 9 this was not found in the present series. The rate of chronic GVHD was quite high although this was increased by attempts to provoke a GVL effect in relapsed patients by withdrawal of immunosuppression and by the administration of DLI. Despite the high incidence of chronic GVHD, there has been only one late NRM, and the median Karnofsky performance status of surviving patients is 90%. As a significant number of patients are still on immunosuppression for control of chronic GVHD, longer follow-up will be necessary to determine the ultimate negative impact of chronic GVHD on the quality and duration of life.
In summary, allogeneic transplant is a potentially curative therapy for high-risk lymphoma patients, including selected patients who have relapsed after autologous transplant. Future studies should compare standard ablative vs reduced-intensity regimens for patients with low grade and MCL. In patients with intermediate-grade lymphomas, the earlier identification of patients with resistant disease and improvements in the management of GVHD will be necessary to further improve cure rates. In patients with persistent or recurrent disease after transplant, targeted therapies in combination with adoptive immunotherapy may be effective.
